ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Serum vitamin d levels predict hospital-free days in outpatient allogeneic stem cell transplantation survivors: implications for long-term health outcomes.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOptimizing long-term health outcomes and minimizing healthcare utilization are crucial for outpatient allogeneic hematopoietic stem cell transplantation (allo-HSCT) survivors. Hospital-free days (HFDs) serve as patient-centered indicators of healthcare burden and physical stability. Although vitamin D (25(OH)D) has immunomodulatory effects, its relationship with HFDs in survivors in remission remains unclear. We investigated the predictive value of serum 25(OH)D levels for HFDs and hospitalization-free survival (HFS).
methodsThis prospective single-center study enrolled 51 adult allo-HSCT survivors in complete remission who visited outpatient clinics. Serum 25(OH)D levels were measured. The primary outcome was HFDs (days alive and out-of-hospital) over 3 years, categorized into four ordered groups. The secondary outcome was HFS (time to death, relapse, or hospitalization). Multivariable ordinal logistic (HFDs) and Cox proportional hazards (HFS) regression analyses were performed, adjusting for confounders using stepwise selection.
resultsThe median patient age was 67.7 years. In multivariable analysis, higher serum 25(OH)D levels significantly predicted better HFD outcomes (adjusted odds ratio = 1.13 per ng/mL; 95% CI = 1.04-1.24; p = 0.001). Higher 25(OH)D levels also independently predicted improved HFS (adjusted hazard ratio = 0.89 per ng/mL; 95% CI = 0.82-0.95; p = 0.001). The Kaplan-Meier analysis confirmed better HFS in patients with 25(OH)D levels above the median (log-rank p = 0.029). Chronic graft-versus-host disease and time since SCT were associated with 25(OH)D levels.
conclusionIn outpatient allo-HSCT survivors, higher serum 25(OH)D levels independently predicted HFDs, suggesting reduced healthcare burden and improved HFS. Vitamin D status warrants further investigation as a potential modifiable target for enhancing long-term HSCT outcomes.
Indexed as
Identifiers
41872355What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.